CIPLA Q2 FY27 Results & Earnings Analysis
Sentiment: Good (Confidence: medium)
Earnings Summary
Cipla reported Q2 FY27 revenue of INR7,404 crores (+4% QoQ) with India delivering highest-ever quarterly revenue (+12% YoY, branded Rx +15% beating market 14.3%), US at $172M (+$10M QoQ), and EMEU $101M. EBITDA margin (ex-other income) at 18.7% (+200 bps QoQ) and PAT margin 11.9% (+77 bps QoQ) with gross margin 64.4% (+7% QoQ) on improved mix. Management maintained US $1B exit run-rate and 18.5-20% EBITDA margin guidance, expecting sequential margin improvement in H2 driven by Ventolin ramp-up, Q3 Advair launch, and 3 pending launches (2 respiratory, 1 peptide). Strategic progress: first DPI approval (generic Advair), Qilu Pembrolizumab biosimilar partnership for North America (2029 patent expiry), CTTQ HER2 ADC in-licensing, 45-50 US filings planned over 3 years, 4 biosimilars under development. Risks: Pithampur 7 Form 483 observations (OAI, no repeats/DI), South Africa tender loss (favorable court ruling), trade generics mid-single-digit YoY, consumer cost/pricing headwinds. Net cash INR9,823 crores; ETR guided 27-27.5%.
Management Tone
- Prepared Remarks: Good — Prepared remarks highlighted highest-ever India quarterly revenue, 12% YoY India growth, 15% branded prescription growth, US revenue of $172M (up $10M QoQ), 200 bps sequential EBITDA margin improvement, and reaffirmed full-year guidance. Tone was confident on pipeline (Advair approval, Qilu partners
- Q&A Session: Neutral — Analysts pressed on US ramp-up specifics (Ventolin supply constraints, timing of 3 pending approvals), margin trajectory, South Africa primary vs secondary growth divergence, and Pithampur observations. Management was confident but often declined product-level quantification ('hard to give product-w
Revenue Growth Drivers
- US Ventolin supply ramp-up from new North America facility
- Generic Advair launch in Q3 from first DPI approval
- India branded prescription growth led by chronic therapies (respiratory +11%, antidiabetes +50%, urology +11%, dermatology +16%)
Growth vs Margin Focus
Management maintains both US $1B exit run-rate (growth) and 18.5-20% EBITDA margin guidance, expecting sequential margin improvement while investing in launches and R&D; 200 bps QoQ margin expansion achieved alongside 4% QoQ revenue growth. Higher R&D (6-7%) and launch investments balanced with marg
About Cipla Limited
Cipla Limited (CIPLA) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.